PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,185 | -39.6% | 131 | 0.0% | 0.00% | -50.0% |
Q2 2023 | $3,618 | +20.1% | 131 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $3,013 | -20.0% | 131 | -62.0% | 0.00% | 0.0% |
Q4 2022 | $3,764 | +25.5% | 345 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $3,000 | 0.0% | 345 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $3,000 | -66.7% | 345 | +38.0% | 0.00% | -60.0% |
Q4 2021 | $9,000 | +125.0% | 250 | 0.0% | 0.01% | +150.0% |
Q3 2021 | $4,000 | -63.6% | 250 | 0.0% | 0.00% | -66.7% |
Q2 2021 | $11,000 | +83.3% | 250 | 0.0% | 0.01% | +100.0% |
Q1 2021 | $6,000 | +200.0% | 250 | +110.1% | 0.00% | +200.0% |
Q4 2020 | $2,000 | 0.0% | 119 | 0.0% | 0.00% | -50.0% |
Q2 2020 | $2,000 | +100.0% | 119 | 0.0% | 0.00% | +100.0% |
Q3 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $1,000 | -66.7% | 119 | -52.8% | 0.00% | 0.0% |
Q3 2018 | $3,000 | – | 252 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |